Novozymes launches animal-free cell culture ingredients product range

Published: 31-May-2007
Ingredients Pharmaceutical

UK-based biotech company Novozymes has launched a range of animal-free recombinant ingredients developed specifically for industrial scale mammalian cell culture.


UK-based biotech company Novozymes has launched a range of animal-free recombinant ingredients developed specifically for industrial scale mammalian cell culture.

This is the first product launch from the company's new biopharmaceutical ingredients business, which is dedicated to developing animal-free recombinant ingredients to support biopharmaceutical production.

'Our biopharmaceutical customers can now achieve the performance of protein-rich media on an industrial scale without the need to compromise on consistency or safety,' said Peter Rosholm, vice president for the biopharmaceutical ingredients business.

See more

You may also like

Ingredients

Novozymes reports a good year in 2014

Read more
Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%

Trending Articles

  1. Sharp appoints Samantha Wilson Jones as General Counsel Sharp Services has appointed Samantha Wilson Jones as General Counsel and Corporate Secretary of Sharp
  2. Nanologica secures first insulin purification order in China The SEK 2m deal will see the company’s silica-based NLAB Saga evaluated at production scale by a Chinese insulin manufacturer
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I) With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
  4. Rousselot Rousselot is a global leader of gelatin and collagen-based solutions, serving the food, health & nutrition, biomedical, and pharmaceutical sectors. With our advanced Science & Innovation team, we unlock the secrets of the collagen molecule to create products that meet the highest standards of safety and quality. Through our state-of-the-art operations and extensive technical and formulation expertise, we help our customers achieve their goals, create world-class products, and we “Reach further together”. Rousselot is Darling’s Ingredients Health Brand.
  5. Rezon Bio launches as European biologics CDMO with mirrored sites in Poland New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Diversity aids a biotech boom

The biotech sector is boosted by invention and shows no sign of slowing. Biopharmaceutical pipelines are broadening and production techniques improving. Susan Birks reports
Research & Development

Novozymes Biopharma enters agreement with leading vaccine company

To conduct research on a novel subunit vaccine complex based on albumin fusion technology
Research & Development

Novozymes Biopharma to offer drug-albumin conjugation platform with ThioLogics

New partnership to offer serum-stable drug-albumin conjugation capability
Manufacturing

GSK uses Novozymes\' Veltis half-life extension technology in once-weekly diabetes drug

Novozymes technology used in recently approved Eperzan type 2 diabetes treatment
Ingredients

Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals
Finance

Novozymes reports 4% increase in sales in Q1

Biopharma sales rise by 22%
Subscribe now